Condition
CYP1A2 Polymorphism
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06610110Not ApplicableCompletedPrimary
Caffeine, CYPA12 and Resistance Exercise
NCT06610123Not ApplicableCompletedPrimary
Caffeine, CYPA12 and Resistance Training
NCT06120543Unknown
CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression
NCT04122053Not ApplicableCompletedPrimary
Personalized Nutrition Caffeine Intake in Healthy Adults.
NCT04240496Not ApplicableCompletedPrimary
Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics
Showing all 5 trials